Leron E, Weintraub AY, Mastrolia SA and Schwarzman P: Overactive bladder syndrome: Evaluation and management. Curr Urol. 11:117–125. 2018.PubMed/NCBI View Article : Google Scholar

Abrams P, Kelleher CJ, Kerr LA and Rogers RG: Overactive bladder significantly affects quality of life. Am J Manag Care. 6 (Suppl):S580–S590. 2000.PubMed/NCBI

Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J and Wein AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87:760–766. 2001.PubMed/NCBI View Article : Google Scholar

Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I and Chapple C: The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: Results from EpiLUTS. BJU Int. 108:1459–1471. 2011.PubMed/NCBI View Article : Google Scholar

Donaldson MM, Thompson JR, Matthews RJ, Dallosso HM and McGrother CW: Leicestershire MRC Incontinence Study Group. The natural history of overactive bladder and stress urinary incontinence in older women in the community: A 3-year prospective cohort study. Neurourol Urodyn. 25:709–716. 2006.PubMed/NCBI View Article : Google Scholar

Lightner DJ, Gomelsky A, Souter L and Vasavada SP: Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline amendment 2019. J Urol. 202:558–563. 2019.PubMed/NCBI View Article : Google Scholar

Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL and Wein AJ: Prevalence and burden of overactive bladder in the United States. World J Urol. 20:327–336. 2003.PubMed/NCBI View Article : Google Scholar

Abrams P, Blaivas JG, Stanton SL and Andersen JT: The standardisation of terminology of lower urinary tract function The International Continence Society Committee on Standardisation of Terminology. Scand J Urol Nephrol Suppl. 114:5–19. 1988.PubMed/NCBI

Drake MJ: Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 33:622–624. 2014.PubMed/NCBI View Article : Google Scholar

Van Dijk MM, Wijkstra H, Debruyne FM, De La Rosette JJ and Michel MC: The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU Int. 105:1141–1146. 2010.PubMed/NCBI View Article : Google Scholar

Cerruto MA, Asimakopoulos AD, Artibani W, Del Popolo G, La Martina M, Carone R and Finazzi-Agrò E: Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity. Urol Int. 89:1–8. 2012.PubMed/NCBI View Article : Google Scholar

Robinson D and Cardozo L: Managing overactive bladder. Climacteric. 22:250–256. 2019.PubMed/NCBI View Article : Google Scholar

Burkhard FC, Bosch JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, Tubaro A, Ambühl D, Bedretdinova DA, Farag F, et al: Urinary Incontinence in Adults. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam, 2020. https://uroweb.org/guideline/urinary-incontinence/. Access date: March 21, 2021.

Abboudi H, Fynes MM and Doumouchtsis SK: Contemporary therapy for the overactive bladder. Obstet Gynaecol. 13:98–106. 2011.

Willis-Gray MG, Dieter AA and Geller EJ: Evaluation and management of overactive bladder: Strategies for optimizing care. Res Rep Urol. 8:113–122. 2016.PubMed/NCBI View Article : Google Scholar

Milsom I, Kaplan SA, Coyne KS, Sexton CC and Kopp ZS: Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: Results from EpiLUTS. Urology. 80:90–96. 2012.PubMed/NCBI View Article : Google Scholar

Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P and Kelleher C: The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 103:202–209. 2009.PubMed/NCBI View Article : Google Scholar

Osman NI and Chapple CR: The management of overactive bladder syndrome: A review of the European Association of Urology Guidelines. Clin Pract. 10:593–606. 2013.

Hu TW and Wagner TH: Health-related consequences of overactive bladder: An economic perspective. BJU Int. 96 (Suppl 1):S43–S45. 2005.PubMed/NCBI View Article : Google Scholar

Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE and Wagner TH: Impact of overactive bladder on work productivity in the United States: Results from EpiLUTS. Am J Manag Care. 15 (Suppl 4):S98–S107. 2009.PubMed/NCBI

Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V and Mullins CD: The total economic burden of overactive bladder in the United States: A disease-specific approach. Am J Manag Care. 15 (Suppl 4):S90–S97. 2009.PubMed/NCBI

Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, Amarenco G, Gamé X, Kirby R, Van Der Aa F and Cornu JN: A comprehensive review of overactive bladder pathophysiology: On the way to tailored treatment. Eur Urol. 75:988–1000. 2019.PubMed/NCBI View Article : Google Scholar

Robinson D, Cardozo L, Milsom I, Pons ME, Kirby M, Koelbl H and Vierhout M: Oestrogens and overactive bladder. Neurourol Urodyn. 33:1086–1091. 2014.PubMed/NCBI View Article : Google Scholar

de Boer TA, Salvatore S, Cardozo L, Chapple C, Kelleher C, van Kerrebroeck P, Kirby MG, Koelbl H, Espuna-Pons M, Milsom I, et al: Pelvic organ prolapse and overactive bladder. Neurourol Urodyn. 29:30–39. 2010.PubMed/NCBI View Article : Google Scholar

Bunn F, Kirby M, Pinkney E, Cardozo L, Chapple C, Chester K, Cruz F, Haab F, Kelleher C, Milsom I, et al: Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. Int J Clin Pract. 69:199–217. 2015.PubMed/NCBI View Article : Google Scholar

de Boer TA, Slieker-ten Hove MC, Burger CW and Vierhout ME: The prevalence and risk factors of overactive bladder symptoms and its relation to pelvic organ prolapse symptoms in a general female population. Int Urogynecol J. 22:569–575. 2011.PubMed/NCBI View Article : Google Scholar

Vrijens D, Drossaerts J, van Koeveringe G, Van Kerrebroeck P, van Os J and Leue C: Affective symptoms and the overactive bladder-a systematic review. J Psychosom Res. 78:95–108. 2015.PubMed/NCBI View Article : Google Scholar

Matsumoto S, Hashizume K, Wada N, Hori J, Tamaki G, Kita M, Iwata T and Kakizaki H: Relationship between overactive bladder and irritable bowel syndrome: A large-scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria. BJU Int. 111:647–652. 2013.PubMed/NCBI View Article : Google Scholar

Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, Chen CI and Quentin Clemens J: The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB-POLL. Neurourol Urodyn. 32:230–237. 2013.PubMed/NCBI View Article : Google Scholar

Gleason JL, Richter HE, Redden DT, Goode PS, Burgio KL and Markland AD: Caffeine and urinary incontinence in US women. Int Urogynecol J. 24:295–302. 2013.PubMed/NCBI View Article : Google Scholar

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A and Wein A: Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: Report from the standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 21:167–178. 2002.PubMed/NCBI View Article : Google Scholar

Wein AJ and Rackley RR: Overactive bladder: A better understanding of pathophysiology, diagnosis and management. J Urol. 175:S5–S10. 2006.PubMed/NCBI View Article : Google Scholar

Foon R and Toozs-Hobson P: Detrusor overactivity. Obstetrics, Gynaecol Reprod Med. 17:255–260. 2007.

Brading AF: Spontaneous activity of lower urinary tract smooth muscles: Correlation between ion channels and tissue function. J Physiol. 570:13–22. 2006.PubMed/NCBI View Article : Google Scholar

Chapple C: Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of ‘overactive bladder’. Neurourol Urodyn. 33 (Suppl 3):S6–S13. 2014.PubMed/NCBI View Article : Google Scholar

Lee SR, Kim HJ, Kim A and Kim JH: Overactive bladder is not only overactive but also hypersensitive. Urology. 75:1053–1059. 2010.PubMed/NCBI View Article : Google Scholar

Hubeaux K, Deffieux X, Desseaux K, Verollet D, Damphousse M and Amarenco G: Stand up urgency: Is this symptom related to a urethral mechanism? Prog Urol. 22:475–481. 2012.PubMed/NCBI View Article : Google Scholar

Apostolidis A, Wagg A, Rahnam A'i MS, Panicker JN, Vrijens D and von Gontard A: Is there ‘brain OAB’ and how can we recognize it? International Consultation on Incontinence-Research Society (ICI-RS) 2017. Neurourol Urodyn. 37 (Suppl 4):S38–S45. 2018.PubMed/NCBI View Article : Google Scholar

Faraj K, Doo F, Boura J, Vereecke A and Chancellor MB: A cross-sectional study in the USA of the epidemiology and quality of life of underactive bladder symptoms. Int Urol Nephrol. 48:1797–1802. 2016.PubMed/NCBI View Article : Google Scholar

Malone-Lee JG and Al-Buheissi S: Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int. 103:931–937. 2009.PubMed/NCBI View Article : Google Scholar

Imamura M, Williams K, Wells M and McGrother C: Lifestyle interventions for the treatment of urinary incontinence in adults. Cochrane Database Syst Rev. 2(CD003505)2015.PubMed/NCBI View Article : Google Scholar

Kincade JE, Dougherty MC, Carlson JR, Hunter GS and Busby-Whitehead J: Randomized clinical trial of efficacy of self-monitoring techniques to treat urinary incontinence in women. Neurourol Urodyn. 26:507–511. 2007.PubMed/NCBI View Article : Google Scholar

Ostaszkiewicz J, Johnston L and Roe B: Timed voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev. 2004(CD002802)2004.PubMed/NCBI View Article : Google Scholar

Wallace SA, Roe B, Williams K and Palmer M: Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev. 2004(CD001308)2004.PubMed/NCBI View Article : Google Scholar

Shafik A and Shafik IA: Overactive bladder inhibition in response to pelvic floor muscle exercises. World J Urol. 20:374–377. 2003.PubMed/NCBI View Article : Google Scholar

Bø K, Kvarstein B and Nygaard I: Lower urinary tract symptoms and pelvic floor muscle exercise adherence after 15 years. Obstet Gynecol. 105:999–1005. 2005.PubMed/NCBI View Article : Google Scholar

Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ and Wein AJ: Muscarinic receptors: Their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 148:565–578. 2006.PubMed/NCBI View Article : Google Scholar

Biastre K and Burnakis T: Trospium chloride treatment of overactive bladder. Ann Pharmacother. 43:283–295. 2009.PubMed/NCBI View Article : Google Scholar

Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE and Weinstein D: The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis. Eur Urol. 54:543–562. 2008.PubMed/NCBI View Article : Google Scholar

Novara G, Galfano A, Secco S, D'Elia C, Cavalleri S, Ficarra V and Artibani W: A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 54:740–763. 2008.PubMed/NCBI View Article : Google Scholar

Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F and Kane RL: Benefits and harms of pharmacologic treatment for urinary incontinence in women: A systematic review. Ann Intern Med. 156:861–874, W301-10. 2012.PubMed/NCBI View Article : Google Scholar

Peeker R, Samsioe G, Kowalski J, Andersson AS and Bergqvist A: A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden. Scand J Urol Nephrol. 44:138–146. 2010.PubMed/NCBI View Article : Google Scholar

Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D and Coyne KS: Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: A systematic review of the literature. Int J Clin Pract. 65:567–585. 2011.PubMed/NCBI View Article : Google Scholar

Robinson D and Cardozo L: Antimuscarinic drugs to treat overactive bladder. BMJ. 344(e2130)2012.PubMed/NCBI View Article : Google Scholar

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X and Haag-Molkenteller C: EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial. J Urol. 189:2186–2193. 2013.PubMed/NCBI View Article : Google Scholar

Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, et al: Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: Results from a randomised European-Australian phase 3 trial. Eur Urol. 63:283–295. 2013.PubMed/NCBI View Article : Google Scholar

Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I and Hakimi Z: Comparative efficacy and safety of medical treatments for the management of overactive bladder: A systematic literature review and mixed treatment comparison. Eur Urol. 65:755–765. 2014.PubMed/NCBI View Article : Google Scholar

Rosa GM, Ferrero S, Nitti VW, Wagg A, Saleem T and Chapple CR: Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol. 9:311–323. 2016.PubMed/NCBI View Article : Google Scholar

Wagg A, Franks B, Ramos B and Berner T: Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada. Can Urol Assoc J. 9:343–350. 2015.PubMed/NCBI View Article : Google Scholar

Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R and Ridder A: Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 67:577–588. 2015.PubMed/NCBI View Article : Google Scholar

Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, Gravas S and Madersbacher S: Contemporary management of lower urinary tract disease with botulinum toxin A: A systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 60:784–795. 2011.PubMed/NCBI View Article : Google Scholar

Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J and Haag-Molkenteller C: Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: A double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 184:2416–2422. 2010.PubMed/NCBI View Article : Google Scholar

Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, Karsenty G, Schulte-Baukloh H, Schurch B and Wyndaele JJ: European Consensus Panel. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: A European consensus report. Eur Urol. 55:100–119. 2009.PubMed/NCBI View Article : Google Scholar

Mascarenhas F, Cocuzza M, Gomes CM and Leão N: Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. Neurourol Urodyn. 27:311–314. 2008.PubMed/NCBI View Article : Google Scholar

Dowson C, Watkins J, Khan MS, Dasgupta P and Sahai A: Repeated botulinum toxin type A injections for refractory overactive bladder: Medium-term outcomes, safety profile, and discontinuation rates. Eur Urol. 61:834–839. 2012.PubMed/NCBI View Article : Google Scholar

Ridout AE and Yoong W: Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy. J Obstet Gynaecol. 30:111–114. 2010.PubMed/NCBI View Article : Google Scholar

Kabay SC, Kabay S, Yucel M and Ozden H: Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease. Neurourol Urodyn. 28:62–67. 2009.PubMed/NCBI View Article : Google Scholar

Govier FE, Litwiller S, Nitti V, Kreder KJ Jr and Rosenblatt P: Percutaneous afferent neuromodulation for the refractory overactive bladder: Results of a multicenter study. J Urol. 165:1193–1198. 2001.PubMed/NCBI

MacDiarmid SA, Peters KM, Shobeiri SA, Wooldridge LS, Rovner ES, Leong FC, Siegel SW, Tate SB and Feagins BA: Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. 183:234–240. 2010.PubMed/NCBI View Article : Google Scholar

Price N, Dawood R and Jackson SR: Pelvic floor exercise for urinary incontinence: A systematic literature review. Maturitas. 67:309–315. 2010.PubMed/NCBI View Article : Google Scholar

Janknegt RA, Hassouna MM, Siegel SW, Schmidt RA, Gajewski JB, Rivas DA, Elhilali MM, Milam DC, van Kerrebroeck PE, Dijkema HE, et al: Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence. Eur Urol. 39:101–106. 2001.PubMed/NCBI View Article : Google Scholar

van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama á Nijholt AA, Siegel S, Jonas U, Fowler CJ, Fall M, Gajewski JB, Hassouna MM, et al: Results of sacral neuromodulation therapy for urinary voiding dysfunction: Outcomes of a prospective, worldwide clinical study. J Urol. 178:2029–2034. 2007.PubMed/NCBI View Article : Google Scholar

Pathak AS and Aboseif SR: Overactive bladder: Drug therapy versus nerve stimulation. Nat Clin Pract Urol. 2:310–311. 2005.PubMed/NCBI View Article : Google Scholar

Somani BK, Kumar V, Wong S, Pickard R, Ramsay C, Nabi G, Grant A and N'Dow J: ABACUS Research Group. Bowel dysfunction after transposition of intestinal segments into the urinary tract: 8-year prospective cohort study. J Urol. 177:1793–1798. 2007.PubMed/NCBI View Article : Google Scholar

Epstein BJ, Gums JG and Molina E: Newer agents for the management of overactive bladder. Am Fam Physician. 74:2061–2068. 2006.PubMed/NCBI

Silva C, Silva J, Ribeiro MJ, Avelino A and Cruz F: Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: Results of a double-blind randomized placebo-controlled trial. Eur Urol. 48:650–655. 2005.PubMed/NCBI View Article : Google Scholar

Lewis JM and Cheng EY: Non-traditional management of the neurogenic bladder: Tissue engineering and neuromodulation. ScientificWorldJournal. 7:1230–1241. 2007.PubMed/NCBI View Article : Google Scholar

Chancellor MB and Hasenau DL: Is behavioral therapy plus antimuscarinic better than drug alone to treat overactive bladder? Rev Urol. 10:306–308. 2008.PubMed/NCBI

Dan Spinu A, Gabriel Bratu O, Cristina Diaconu C, Maria Alexandra Stanescu A, Bungau S, Fratila O, Bohiltea R and Liviu Dorel Mischianu D: Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review). Exp Ther Med. 20:117–120. 2020.PubMed/NCBI View Article : Google Scholar

Scarneciu I, Bungau S, Lupu AM, Scarneciu CC, Bratu OG, Martha O, Tit DM, Aleya L and Lupu S: Efficacy of instillation treatment with hyaluronic acid in relieving symptoms in patients with BPS/IC and uncomplicated recurrent urinary tract infections-Long-term results of a multicenter study. Eur J Pharm Sci. 139(105067)2019.PubMed/NCBI View Article : Google Scholar